Appendix 4E and Financial Report
Anatara's CEO, Mr Steven Lydeamore said, "We are happy to release our FY 2019 financial results following what has been a year of transition for Anatara Lifesciences. We commenced the financial year with a clear focus on successfully transitioning Anatara into a human health company, through pursuing the global gastrointestinal health market. By February 2019, we released excellent efficacy data received from our in vitro proof-of-concept studies for our first human product candidate, our innovative Gastrointestinal ReProgramming (GaRP) dietary supplement."
"GaRP has been uniquely designed to address the primary underlying factors associated with gastrointestinal disorders such as Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD). Unlike others commonly marketed, Anatara's dietary supplement has a tripletargeted therapeutic approach (anti-adhesion; anti-inflammatory; mucosal regeneration) and will deliver components to where they can be most effective. Feedback from gastroenterologists to date has been very positive and indicate that GaRP may be a breakthrough dietary product in the gastrointestinal health space."
"Shareholders can find confidence in the Company's future strategy as we continue the development of our GaRP dietary supplement to meet the unmet need for IBS and IBD patients.
Following on from our successful in vitro studies, we have commenced pre-clinical animal studies in IBD and anticipate initiation of a human clinical study in IBS in late 2019, with a view to partnering in the second half of calendar 2020."
"IBS affects around 11% of the global population1 and 50% of patients2 turn to dietary supplements and complementary medicines to manage the symptoms of their disease. IBD affects >5 million patients worldwide3 and due to the failure of current drugs, 30-50% of patients4 turn to complementary and alternative medicines."
"Furthermore, the Company was pleased to have met a key commercial milestone in obtaining regulatory approval for our animal health product, Detach(R), in October 2018 by the Australian Pesticides and Veterinary Medicines Authority (APVMA). We reported in June 2019 that Zoetis Inc. gave notice of termination of the global licencing agreement. Following this, the Company held an advisory meeting with external animal health experts in August 2019 informing our strategy for partnering Detach(R) in 2020."
"Anatara remains confident a strong market exists for a non-antibiotic solution to control scour in livestock, with Detach(R) benefiting from growing concerns over traditional antimicrobials and the global threat of antibiotic resistance. We are committed to delivering value to our shareholders through partnering this asset with multi-national animal health companies."
"Looking ahead to 2020, Anatara remains focused on its new business strategy in human health, and in particular, the partnering of its GaRP dietary supplement to target the significant unmet market need for evidence-based complementary medicines in gastrointestinal health."
To view the full report, please visit:
About Anatara Lifesciences Ltd
Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.
Anatara Lifesciences Ltd